Chloroquinoxaline sulfonamide (Chloroquinoxaline) 是 sulfaquinoxaline 的结构类似物,是拓扑异构酶 II alpha/beta (topoisomerase II alpha/beta) 毒物。Chloroquinoxaline sulfonamide 用于控制家禽,兔,绵羊和牛的球虫病。 具有抗肿瘤活性。
生物活性 | Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is atopoisomeraseII alpha/betapoison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle[1]. Antitumor activity[2]. |
IC50& Target[1] | topoisomerase II alpha | topoisomerase II beta | Coccidia |
|
体外研究 (In Vitro) | The Chloroquinoxaline sulfonamide IC50 for CV-1cells, obtained using an MTT cytotoxicity assay, was 1.8 mM. Chloroquinoxaline sulfonamide causes dose-dependent protein-DNA cross-links to CV-1 monkey kidney cell chromosomal DNA when drug treatment was terminated by lysis with GuHCl. Chloroquinoxaline sulfonamide-induced protein-DNA cross-links in CV-1 cells. Chloroquinoxaline sulfonamide-induced topoisomerase II-DNA cross-links[1]. Chloroquinoxaline sulfonamide (Chloroquinoxaline), a chlorinated derivative of sulfaquinoxaline, inhibits proliferation of murine B16 melanoma cells, but only when relatively high drug concentrations (1 mM) are used[2].
Cell Proliferation Assay[2] Cell Line: | B16 murine melanoma cells | Concentration: | 10 μM, 100 μM, 1 mM | Incubation Time: | 24, 48, 72 hours | Result: | Inhibited proliferation of murine B16 melanoma cells, but only when relatively high drug concentrations (1 mM) were used. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(373.38 mM;Need ultrasonic) 配制储备液 1 mM | 2.9870 mL | 14.9352 mL | 29.8704 mL | 5 mM | 0.5974 mL | 2.9870 mL | 5.9741 mL | 10 mM | 0.2987 mL | 1.4935 mL | 2.9870 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (6.21 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.21 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (6.21 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.21 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|